鼻NK/T细胞淋巴瘤的免疫表型、EBV感染及TCRγ基因重排的检测

 目的 检测鼻NK/T细胞淋巴瘤（NK/TCL）的免疫表型、EBV感染及TCRγ基因重排,为诊断和鉴别诊断提供依据。方法 收集诊断鼻NK/TCL48例患者石蜡包埋标本,用免疫组化SP法标记LCA、CD79α、CD20、CD56、CD3、CD45RO及EBV抗体研究其免疫表型;EBER探针原位杂交方法检测EBV编码的小分子RNA（EBER）;聚合酶链式反应扩增方法检测TCRγ基因重排。结果 48例鼻NK/TCL均表达LCA,CD3、CD45RO、CD56和EBV阳性率分别为44%、52%、73%和19%,CD79α和CD20均阴性;EBER阳性率为81%;TCRγ基因重排阳性率为19%。结论 鼻NK/TCL免疫表型不一致,并非所有病例CD56阳性,石蜡切片中CD3阳性定位于细胞质;EBER在肿瘤细胞中高表达,提示它们可能为NK细胞来源;部分TCRγ基因重排阳性病例应为鼻NK样T细胞淋巴瘤。     

原发系统性间变性大细胞淋巴瘤临床病理特征及免疫表型分析

 目的　分析原发系统性间变性大细胞淋巴瘤（ALCL）的临床病理特征和免疫组织化学特点,提高诊治水平。方法　选取22例ALCL患者,均进行分期、国际预后指数（IPI）、乳酸脱氢酶（LDH）检测,应用免疫组织化学SP法检测间变性淋巴瘤激酶（ALK）、Ki-67、Caspase-3、CD30、EMA、Granzyme B等,回顾性分析患者临床、病理形态学资料、免疫表型及生物学特性,并进行预后分析。结果　22例均为原发系统性ALCL,ALK+ 15例（68.2 %）,ALK- 7例（31.8 %）;ALK+患者发病年龄、Ki-67增殖指数较ALK-患者低,Caspase-3表达率高,差异有统计学意义（χ2＝4.618,P＝0.032）;15例ALK+ALCL均表达CD30和EMA。ALCL中ALK的表达与Ki-67、Caspase-3的表达呈负相关（r＝-0.581,P＝0.006;r＝0.458,P＝0.032）。ALK+病例较ALK-病例Granzyme B（χ2＝0.11,P＝0.74）、 TIA-1（χ2＝0.01,P＝0.92）的表达率高,但差异无统计学意义（P＞0.05）。有效率为 54.5 ％（12／22）,其中完全缓解率为18.2 %（4／22）;全组中位生存期12个月,1年生存率为59.1 %（13／22）,2年生存率为50.0 ％（11／22）。Ann Arbor分期、LDH及IPI与疾病预后相关。结论　ALK+较ALK-ALCL患者核增殖低,恶性程度低,临床特征和免疫表型具有一定的特征性;ALK、Ki-67、Caspase-3、分期、血清LDH及IPI对预测ALCL患者的生存和指导治疗有帮助。     

西部单中心51例套细胞淋巴瘤患者临床特征及预后因素分析

目的:研究套细胞淋巴瘤（MCL)患者的临床特点及预后相关因素,进一步全面评估病情,探索个体化治疗。方法:回顾性分析2012年1 月至2016年12 月经我院病理科确诊的51例MCL 患者的临床特点、住院20例患者的预后分层和不同化疗方案的近期及远期疗效,并进行随访观察。结果:20例住院治疗患者中,R-Hyper-CVAD组及R-CHOP样组的ORR（分别为100%、100%）均高于其未联合美罗华组（分别为50%、40%）;MIPI评分中,低危组ORR为75.0%,明显高于中危组（16.6%）;CD5-患者CR、PR均高于CD5+患者;Ki67≥30%患者CR率（20%）大于Ki67＜30%组（11%）,PR率则相反;Ki67＜30%患者3年OS明显高于Ki67≥30%患者,有统计学差异,而PFS无统计学差异;MIPI分组中,低危组3年OS明显高于中高危组,有统计学差异,PFS无统计学差异;美罗华组无论OS还是PFS均高于非美罗华组;Hyper-CVAD组与非Hyper-CVAD组OS、PFS均无统计学差异。结论:美罗华联合化疗治疗MCL的疗效是肯定的,绝大多数患者能够耐受减低剂量的Hyper-CVAD A及B方案化疗,但统计学显示与非Hyper-CVAD组无明显差异,可能与病例数偏少相关,需要更多大样本的循证医学的支持。     

套细胞淋巴瘤25例临床特征及预后分析

目的 分析套细胞淋巴瘤（MCL）的临床病理特点、治疗反应及预后相关因素.方法 回顾性分析北京友谊医院25例MCL患者的临床资料、治疗反应及预后因素.结果 25例患者中位发病年龄65岁,男女比例3.4∶1,其中骨髓侵犯15例（60％）,Ann Arbor分期Ⅲ期6例（24％）,Ⅳ期17例（68％）,10例（40％）患者有B症状,5例（20％）患者乳酸脱氢酶（LDH）升高,16例（64％）患者β2-微球蛋白（β 2-MG）升高.17例利妥昔单抗联合化疗者完全缓解率为64.71％、2年总生存（OS）率为69.6％、2年无进展生存（PFS）率为45.1％,高于常规化疗者（P＜0.005）.预后分析显示：母细胞变异型、骨髓侵犯、LDH升高、Ki-67指数、简化的MCL国际预后指数（sMIPI）＞ 5分.白细胞升高为预后不良因素,而国际预后指数（IPI）评分、脾大、年龄、B症状及β2-MG对预后无显著影响.结论 MCL恶性度高,预后差.利妥昔单抗联合化疗可明显提高CR率、PFS率及OS率.     

口腔颌面部弥漫大B细胞淋巴瘤69例临床病理分析

目的探讨口腔颌面部弥漫大B细胞淋巴瘤（DLBCL）的临床病理学特点及其预后相关因素。方法对69例口腔颌面部DLBCL进行回顾性临床病理分析,包括形态学复习、免疫表型和EB病毒编码小RNA（EBV—EBER）原位杂交检测,结合临床随访结果进行预后相关因素分析,并与同期诊断的40例原发淋巴结DLBCL进行比较。结果69例口腔颌面部DLBCL患者中位发病年龄61岁（4—91岁）,男女比例为1．56：1。发病部位以舌根最为常见（19例,27．5％）,其次为腮腺、齿龈、腭等。肿瘤细胞多起源于非生发中心B细胞,比例为64．2％（43／67）,bcl-2、c—myc及EBV—EBER阳性率分别为66．7％（38／57）、23．4％（11／47）及5．3％（3／57）,Ki-67高表达（t〉70％）者占71．0％（49／69）。42例获得完整随访资料,生存时间1—85个月,生存分析显示年龄I〉65岁、Ki-67高表达者预后差,R-CHOP方案治疗组预后好于CHOP方案及放疗组。与同期诊断为原发淋巴结DLBCL相比,除了肿瘤细胞的起源分组有明显差异外,其余临床病理特点及预后差异均无统计学意义（均P〉0．05）。结论口腔颌面部DLBCL最常见于舌根,多为非生发中心B细胞起源,临床病理特点及预后与淋巴结DLBCL相似。年龄≥65岁和Ki．67高表达是独立的预后不良提示因素。R—CHOP方案治疗组预后好于CHOP方案治疗组。     

EB病毒感染与早期鼻型结外NK/T细胞淋巴瘤患者疗效及预后的关系

目的 探讨早期结外鼻型NK/T细胞淋巴瘤（ENKTCL）患者治疗前EBV DNA载量、治疗前血清EA-IgA及VCA-IgA抗体水平与临床特征、治疗反应及预后的关系。方法 分析78例早期结外鼻型NK/T细胞淋巴瘤患者的临床特征及影响预后的因素。结果 治疗前EBV DNA、VCA-IgA、EA-IgA阳性率分别为43.6%、20.5%、14.1%。EBV DNA与Ann Arbor分期、原发部位、PTI、治疗后未获得CR显著相关（均P<0.05）。VCA-IgA、EA-IgA滴度分别与EBV DNA、治疗后未获得CR显著相关（均P<0.05）。多因素分析发现年龄、EBV DNA、治疗后未获得CR为早期ENKTCL患者OS的独立预后因素（均P<0.05）;年龄、EBV DNA、原发鼻腔外上呼吸消化道、治疗后未获得CR（均P<0.05）则为早期ENKTCL患者PFS的独立预后因素。结论 治疗前EBV DNA阳性与较晚的Ann Arbor分期、PTI、原发鼻腔外上呼吸消化道、治疗反应差有关。EA-IgA、VCA-IgA水平升高与EBVDNA阳性、治疗反应差有关。治疗前EBV DNA可用于ENKTCL的风险分层及预后预测,而EA-IgA、VCA-IgA对于ENKTCL的预后指导作用有限。     

伊布替尼治疗慢性淋巴细胞白血病的效果及安全性研究

目的:探讨伊布替尼治疗慢性淋巴细胞白血病（CLL）的效果及安全性。方法:回顾性分析1998年5月至2019年10月在福建医科大学附属协和医院确诊的68例CLL患者的临床资料,其中采用伊布替尼一线治疗39例,二线治疗20例,二线以上治疗9例。分析临床特征、IGHV基因突变及染色体核型分层患者近期疗效及生存情况,总结不良反应发生情况。结果:随访截至2020年5月,中位随访时间53.2个月。伊布替尼治疗的客观缓解率（ORR）为83.8%（57/68）,其中完全缓解8例（11.8%）,部分缓解49例（72.1%）,疾病稳定5例（7.4%）,疾病进展6例（8.8%）。IGHV未突变患者ORR高于突变患者[93.3%（28/30）比76.3%（29/38）, χ2＝33.656, P<0.05],国际预后指数（IPI）评分低危及低中危患者ORR高于中高危及高危者[90.6%（29/32）比77.8%（28/36）, χ2＝7.248, P＝0.007],其他因素分层患者间ORR差异均无统计学意义（均 P>0.05）。68例患者中31例（45.6%）出现不良反应,均能坚持治疗;其中26例（38.2%）发生1~2级不良反应,5例（7.4%）发生3级及以上不良反应;因不良反应停药2例（2.9%）。全组患者的中位无进展生存（PFS）及总生存（OS）时间均未达到。伴有IGHV突变患者5年PFS率高于IGHV未突变者（100.0%比72.1%, P＝0.020）,染色体核型正常者5年PFS率高于染色体核型异常的患者（100.0%比74.3%, P＝0.019）。 结论:伊布替尼治疗CLL具有良好的疗效和安全性。     

阑尾原发Burkitt淋巴瘤临床病理观察

目的：探讨阑尾原发Burkitt淋巴瘤（BL）的临床病理特点、免疫表型及分子生物学特征。方法：运用组织形态及免疫组化,EB病毒（EBER）原位杂交方法研究1例发生在阑尾的Burkitt淋巴瘤,并结合文献进行分析讨论。结果：阑尾Burkitt淋巴瘤（BL）形态学表现为肿瘤细胞弥漫一致性增生的中等大小细胞浸润,部分瘤细胞周围空晕伴有星空现象。免疫组化显示,肿瘤细胞LCA,CD20及CD10均为阳性,Ki-67大于80%阳性,CD99,CD3p,Mpo阴性,原位杂交EBER阴性。结论：原发于阑尾Burkitt淋巴瘤（BL）非常罕见,属高度侵袭性。应与其他类型淋巴瘤相鉴别,需结合组织形态及免疫组化,原位杂交等为临床诊断和及时治疗提供依据。     

EB病毒编码的小RNA检测在噬血细胞综合征骨髓活检中的意义

 目的　探讨噬血细胞综合征骨髓活检样本病理改变特点及与EB病毒（EBV）感染的关系,以及EBV编码的小RNA（EBER）检测技术在噬血细胞综合征骨髓样本检测中的价值。方法　应用HE、免疫组织化学EnVision二步法、EBER原位杂交技术,观察51例噬血细胞综合征患者骨髓活检样本形态学改变及噬血现象,并检测EBV潜在膜蛋白1（LMP-1）、EBER及其他相关标志。结果　51例噬血细胞综合征患者中,49.0 %（25／51）可见骨髓腔内造血细胞丰富,27.5 %（14／51）各系造血细胞增生情况与本年龄段相符,23.5 %（12／51）造血细胞减少和分布稀疏,较相同年龄患者应有的骨髓造血细胞减少明显。43.1 %（22／51）可以见到噬血现象。91.4 %（32／35）见增生细胞表达CD68／KP-1,89.5 %（17／19）增生细胞表达CD68／PG-M1,提示单核细胞增生明显。所有病例进行EBER检测,51.0 %（26／51）阳性,41例同时进行LMP-1和EBER检测,其中46.3 %（19／41）EBER阳性,而LMP-1全部阴性（Fisher精确概率法,P＝0.000）。结论　噬血细胞综合征患者骨髓活检组织可以见到造血细胞增生减低及噬血现象。病理形态学的噬血现象有时较难判定,借助于免疫组织化学检测组织细胞的增生很有意义。同时,采用EBER检测EBV对诊断的意义大于检测LMP-1。     

新药诱导后自体造血干细胞移植对以荧光原位杂交分层的多发性骨髓瘤患者的价值

 　目的　评价新药诱导后自体造血干细胞移植（ASCT）对荧光原位杂交（FISH）标危及高危多发性骨髓瘤患者生存的影响。方法　回顾性分析74例多发性骨髓瘤患者,均接受以硼替佐米和（或）沙利度胺为主的诱导化疗,按FISH检测结果及诱导后是否接受ASCT分为标危移植组、标危化疗组、高危移植组及高危化疗组4组,通过生存分析分别评价ASCT对标危及高危患者生存的影响。结果　74例患者经新药诱导后总缓解率为91.9 %（68／74）,接近完全缓解（nCR）+ 完全缓解（CR）率为62.2 %（46／74）。FISH标危的患者与高危的患者诱导后缓解率分别为93.2 %（41／44）与86.7 %（26／30）（P＝0.592）,nCR+CR率分别为56.8 %（25／44）与70.0 %（21／30）（P＝0.251）。FISH标危的患者中,接受移植的患者与接受化疗巩固的患者无进展生存（PFS）及总生存（OS）差异均无统计学意义（P值分别为0.642和0.652）,而FISH高危的患者中,接受移植的患者比接受化疗巩固的患者PFS延长19.7个月（P＝0.028）,OS延长12.5个月（P＝0.542）。结论　在以硼替佐米和（或）沙利度胺为主的方案诱导后,ASCT对 FISH标危多发性骨髓瘤患者的PFS和OS均没有影响,但可使FISH高危患者的PFS延长。     

Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type.

BACKGROUND: Localized extranodal natural killer (NK)/T-cell lymphoma, nasal type, commonly has a low or low-intermediate risk of the international prognostic index (IPI), so the IPI has shown inconsistency in predicting prognosis. Thus, we analyzed Ki-67 expression and proposed a new prognostic model including Ki-67 expression for stage I/II extranodal NK/T-cell lymphoma. PATIENTS AND METHODS: We studied Ki-67 expression and its relationship with prognosis in 50 patients with extranodal NK/T-cell lymphoma. RESULTS: The patients were dichotomized by the median value: low (<65%) versus high Ki-67 (> or =65%). High Ki-67 was associated with a worse overall survival (OS; P = 0.021) and disease-free survival (DFS; P = 0.044). In multivariate analysis, Ki-67 expression and primary site of involvement were found to be an independent prognostic factor for OS and DFS (P < 0.05). Based on these results, we proposed a new clinico-pathological prognostic model with Ki-67 expression and the primary site of involvement. It showed a high degree of correlation with worse OS and DFS (P < 0.001). CONCLUSIONS: Ki-67 expression is predictive of prognosis, and our prognostic model may become a useful tool for predicting prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type.     

Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer/T cell lymphoma

Background: Nasal?type extranodal natural killer/T?cell lymphoma (ENKTCL) originates primarily in the nasal cavity or extra?nasal sites within the upper aerodigestive tract. However, it is unclear whether the primary site can serve as an independent prognostic factor or whether the varying clinical outcomes observed with different primary sites can be attributed merely to their propensities of regional lymph node involvement. The aim of this study was to investigate the prognostic implications of the primary site and regional lymph node involvement in patients with early?stage nasal?type ENKTCL. Methods: To develop a nomogram, we reviewed the clinical data of 215 consecutively diagnosed patients with early?stage nasal?type ENKTCL who were treated in Sun Yat?sen University Cancer Center with chemotherapy and radiotherapy between 2000 and 2011. The predictive accuracy and discriminative ability of the nomogram were determined using a concordance index (C?index) and calibration curve. Results: The 5?year overall survival (OS) and progression?free survival (PFS) rates of patients with nasal ENKTCL were higher than those of patients with extra?nasal ENKTCL (OS: 68.2% vs. 46.0%, P = 0.030; PFS: 53.4% vs. 26.6%, P = 0.010).The 5?year OS and PFS rates of patients with Ann Arbor stage IE ENKTCL were higher than those of patients with Ann Arbor stage IIE ENKTCL (OS: 66.3% vs. 59.2%, P = 0.003; PFS: 51.4% vs. 40.3%, P = 0.009). Multivariate analysisshowed that age >60 years, ECOG performance status score nasal primary site, and regional lymph node involvement were significantly associated with lower 5?year OS rate;≥2, elevated lactate dehydrogenase (LDH) level, extra?age >60 years, elevated LDH level, extra?nasal primary site, and regional lymph node involvement were significantly associated with lower 5?year PFS rate. The nomogram included the primary site and regional lymph node involve?ment based on multivariate analysis. The calibration curve showed good agreement between the predicted and actual 5?year OS and PFS rates, and the C?indexes of the nomogram for the OS and PFS rates were 0.697 and 0.634, respectively. Conclusions: The primary site and regional lymph node involvement are independent prognostic factors for early?stage ENKTCL treated with chemotherapy followed by definitive radiotherapy.     

Ki-67 index as a prognostic factor of subsequent lapatinib-based therapy in HER2-positive metastatic breast cancer with resistance to trastuzumab

Prognostic factor analysis has been conducted to determine whether the parameters of clinical data and biomarkers would predict differential progression-free survival (PFS) or overall survival (OS) from lapatinib-based therapy in patients with primary or acquired resistance to trastuzumab. Treatment with lapatinib plus capecitabine for HER2-positive metastatic breast cancer (MBC) with primary or acquired resistance to trastuzumab was analyzed retrospectively. Tumor biomarkers, which came from the biopsies before the starting of lapatinib therapy, were evaluated by immunohistochemistry (IHC). Prognostic factors related to PFS or OS of the lapatinib therapy were assessed by univariate and multivariate analysis. Ki-67 index and liver metastases were the significant prognostic factors for predicting PFS of subsequent lapatinib therapy in the univariate analysis and the multivariate analysis. The risk for disease progression in patients who had a Ki-67 index < 40% was 59% less than that in patients had Ki-67 ≥ 40 (HR = 0.41, 95% CI, 0.23–0.74, P = 0.003). TTP of prior trastuzumab therapy, liver metastases, and the number of metastatic sites were three independent prognostic factors of subsequent lapatinib therapy. Ki-67 index was the significant prognostic factors for predicting PFS of the subsequent second line targeted therapy in patients with trastuzumab resistance.     

EBER1/2、LMP-1在NK/T细胞淋巴瘤中的表达

目的　探讨NK /T细胞淋巴瘤与EB病毒 (EBV )的关系。方法　收集 2 6例NK /T细胞淋巴瘤 (淋巴结内 10例 ,淋巴结外 16例 ) ,采用免疫组织化学S P法确定瘤细胞本质 ,用原位杂交法检测EBV编码的RNA (EBER 1/2 )。结果　①在 2 6例NK /T细胞淋巴瘤中 ,EBER1/2检出率为 46 .2 % (12 /2 6 ) ,其中淋巴结内检出率为 10 .0 % (1/10 ) ,淋巴结外检出率为 6 8.8% (11/16 ) ,2组比较有非常显著性差异 (P <0 .0 1)。②在淋巴结外NK/T细胞淋巴瘤中 ,EBER 1/2在鼻腔检出率为 90 .0 % (9/10 ) ,其它部位为 33 .3 % (2 /6 ) ,2组比较有显著性差异 (P <0 .0 5 )。③EB病毒潜伏膜蛋白 (LMP 1)在EBER1/2阳性病例中的检出率为16 .7% (2 /12 )。结论　EBV在NK /T细胞淋巴瘤的发生中有一定作用 ,并具有部位依赖性的特点 ;EBV在NK /T细胞淋巴瘤中的潜伏感染模式不完全一致。     

Prognostic significance of histologic grade and Ki-67 proliferation index in follicular lymphoma

The prognostic value of histologic grading and the Ki-67 proliferation index in follicular lymphoma (FL) is controversial. This study investigated the clinical usefulness of these two factors in Asian FL patients. Four hundred and thirty-three patients diagnosed with FL were retrospectively reviewed with a median follow-up time of 47.0 months (range, 24.0-168.0). The 10-year overall survival (OS) rate and progression-free survival (PFS) rate were 91.0% and 47.1%, respectively. Grade 3B and grade 3B with diffuse large B cell lymphoma (DLBCL) showed a better PFS than grade 1-3A (P < 0.001), and similar findings were noted in patients who received rituximab-containing regimens (P = 0.002). In contrast, no significant differences in terms of OS or PFS were observed between grades 1-2 and 3A. In addition, patients with Ki-67 ≥ 30% had a significantly better PFS than patients with Ki-67 < 30% (P = 0.014), although the difference was eliminated in the multivariate analysis. Both grade and Ki-67 index had no impact on prognosis in patients who did not receive rituximab treatment. In conclusion, grade 3A is closely related to grade 1-2, as reflected by a similar indolent clinical course and a lower PFS rate than grade 3B/3B + DLBCL. In addition, a higher Ki-67 index seems to have a positive effect on PFS in FL patients.     

80例原发中枢神经系统弥漫大B细胞淋巴瘤的临床病理、免疫表型及EB病毒感染的研究

目的:对80例原发中枢神经系统弥漫大B细胞淋巴瘤（primary diffuse large B cell lymphoma of the central nervous system,PCNS DLBCL）进行临床病理学回顾性研究、免疫表型检测及EB病毒（Epstein-Barr virus,EBV）感染检测。旨在探讨其与预后的关系。方法:对80例PCNS DLBCL进行免疫表型检测及EB病毒检测,并进行Hans、Choi和Tally分型、统计学单因素和多因素预后分析。结果:Bcl-2、CD10、Bcl-6、Mum-1、GCET-1、BLIMP-1、FOXP-1和LMO-2的表达率分别为46.1%、8.8%、75.0%、57.5%、27.5%、11.3%、75.0%和26.3%;Ki-67指数为30%～95%,中位数为80%。Hans、Choi和Tally分型中Non-GCB型/ABC型弥漫大B细胞淋巴瘤（diffuse large B cell lymphoma,DLBCL）（63.9%、79.2%和90.0%）为最常见的亚型。EBV及EBER1/2-ISH的表达率均为3.8%。58.8%的患者术后未行其它治疗,其1年、2年和5年生存率分别为36.3%、16.4%和4.6%。术后是否行其它治疗、采用甲氨喋呤（methotrexate,MTX）治疗和环磷酰胺+多柔比星+长春新碱+泼尼松龙（cyclophosphamide,doxorubicin,vincristine,and prednisone,CHOP）治疗是有统计学意义的预后相关因素（P均＜0.001）。结论:80例PCNS DLBCL患者年龄较国内外报道的小;以Non-GCB型/ABC型DLBCL为主;个别病例检出EB病毒感染;术后未行其它治疗组、未采用MTX治疗组和未CHOP治疗组的预后较差。     

Epstein-Barr Virus-Associated Extranodal Non-Hodgkin's Lymphoma of the Sinonasal Tract and Nasopharynx in Thailand

Epstein-Barr virus (EBV) infection is highly associated with specific subtypes of malignant lymphoma. In our ‍previous report on nodal malignant lymphoma in Thailand, we found that 64% of classical Hodgkin’s lymphoma ‍(cHL), 51% of non-Hodgkin’s lymphoma, T-cell (NHL-T), and 13% of non-Hodgkin’s lymphoma, B-cell (NHL-B) ‍were EBV-related. In the present research, we conducted a retrospective study of primary extranodal non-Hodgkin’s ‍lymphoma of the sinonasal tract (e-NHL-ST) and primary extranodal non-Hodgkin’s lymphoma of the nasopharynx ‍(e-NHL-NP) in Southern Thailand, between 1997 and 2004. EBV-encoded RNA (EBER) expression by in situ ‍hybridization was performed in all cases and a T-cell receptor (TCR)-g gene rearrangement study was performed in ‍NHL-T cases. There were 18 cases of e-NHL-ST and 42 cases of e-NHL-NP detected by histologic and ‍immunohistochemistry examinations. The percentages of e-NHL-ST and e-NHL-NP as compared to nodal malignant ‍lymphoma were 3.7% and 6.8%, respectively. Sixteen cases (88.9%) of e-NHL-ST and 7 cases (16.7%) of e-NHL-NP ‍were NHL-T, and the remainder were NHL-B. All of the NHL-T cases in both sites were EBER-positive. Two (5.4%) ‍of the NHL-B cases in the nasopharynx showed EBER positive. Monoclonal bands of the TCR-ã gene were detected ‍in 71.4% of the extranodal NK/T-cell lymphomas, nasal type, patients; 50.0% of peripheral T-cell lymphoma, ‍unspecified, patients; and one case of angioimmunoblastic T-cell lymphoma. This study indicates a very strong ‍association of NHL-T in the sinonasal tract or nasopharynx with EBV infection, the link apparently being weaker in ‍NHL-B patients. The study also indicates that most cases of extranodal NK/T-cell lymphoma, nasal type, are not the ‍germline configuration of the TCR genes.     

Chewing of Betel,Areca and Tobacco: Perceptions and Knowledge Regarding their Role in Head and Neck Cancers in an Urban Squatter Settlement in Pakistan

Epstein-Barr virus (EBV) infection is highly associated with specific subtypes of malignant lymphoma. In our ‍previous report on nodal malignant lymphoma in Thailand, we found that 64% of classical Hodgkin’s lymphoma ‍(cHL), 51% of non-Hodgkin’s lymphoma, T-cell (NHL-T), and 13% of non-Hodgkin’s lymphoma, B-cell (NHL-B) ‍were EBV-related. In the present research, we conducted a retrospective study of primary extranodal non-Hodgkin’s ‍lymphoma of the sinonasal tract (e-NHL-ST) and primary extranodal non-Hodgkin’s lymphoma of the nasopharynx ‍(e-NHL-NP) in Southern Thailand, between 1997 and 2004. EBV-encoded RNA (EBER) expression by in situ ‍hybridization was performed in all cases and a T-cell receptor (TCR)-g gene rearrangement study was performed in ‍NHL-T cases. There were 18 cases of e-NHL-ST and 42 cases of e-NHL-NP detected by histologic and ‍immunohistochemistry examinations. The percentages of e-NHL-ST and e-NHL-NP as compared to nodal malignant ‍lymphoma were 3.7% and 6.8%, respectively. Sixteen cases (88.9%) of e-NHL-ST and 7 cases (16.7%) of e-NHL-NP ‍were NHL-T, and the remainder were NHL-B. All of the NHL-T cases in both sites were EBER-positive. Two (5.4%) ‍of the NHL-B cases in the nasopharynx showed EBER positive. Monoclonal bands of the TCR-ã gene were detected ‍in 71.4% of the extranodal NK/T-cell lymphomas, nasal type, patients; 50.0% of peripheral T-cell lymphoma, ‍unspecified, patients; and one case of angioimmunoblastic T-cell lymphoma. This study indicates a very strong ‍association of NHL-T in the sinonasal tract or nasopharynx with EBV infection, the link apparently being weaker in ‍NHL-B patients. The study also indicates that most cases of extranodal NK/T-cell lymphoma, nasal type, are not the ‍germline configuration of the TCR genes.     

经典型霍奇金淋巴瘤组织中CSF-1 R蛋白和FOXP3的表达及其与预后的相关性

目的 观察叉头转录因子3(FOXP3)、集落刺激因子1受体(CSF-1R)蛋白在经典型霍奇金淋巴瘤(CHL)中的表达,并探讨其与患者预后的相关性.方法 分析45例CHL患者的临床资料,包括临床特征、预后因素及治疗方案等.收集45例CHL患者的标本,采用免疫组织化学染色法检测FOXP3、CSF-1R的表达,并采用原位杂交...